Statistical Evaluation of Dissolution for Specification Setting and Stability Studies Fasheng Li Associate Director, Pharmaceutical Statistics Worldwide.

Slides:



Advertisements
Similar presentations
Assumptions underlying regression analysis
Advertisements

Company Confidential © 2012 Eli Lilly and Company Beyond ICH Q1E Opening Remarks Rebecca Elliott Senior Research Scientist Eli Lilly and Company MBSW 2013.
Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Dissolution stability of a modified release product 32 nd MBSW May 19, 2009
2-4 ICH Quality Guidances: an overview
Current Statistical Issues in Dissolution Profile Comparisons
Statistical Analysis and Data Interpretation What is significant for the athlete, the statistician and team doctor? important Will Hopkins
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
Finished Pharmaceutical Product Specifications
Departments of Medicine and Biostatistics
Batch Reworking and Reprocessing
Mitigating Risk of Out-of-Specification Results During Stability Testing of Biopharmaceutical Products Jeff Gardner Principal Consultant 36 th Annual Midwest.
Objectives (BPS chapter 24)
Determine impurity level in relevant batches1
© 2010 Pearson Prentice Hall. All rights reserved Least Squares Regression Models.
8-1 Copyright ©2011 Pearson Education, Inc. publishing as Prentice Hall Chapter 8 Confidence Interval Estimation Statistics for Managers using Microsoft.
Copyright ©2011 Pearson Education 8-1 Chapter 8 Confidence Interval Estimation Statistics for Managers using Microsoft Excel 6 th Global Edition.
Establishing and Predicting Quality: Process Validation - Stage 1
1 BA 555 Practical Business Analysis Review of Statistics Confidence Interval Estimation Hypothesis Testing Linear Regression Analysis Introduction Case.
Discussion on four presentations on Study design and statistical modeling for accelerated stability testing Regular long term stability – shelf life is.
Oscar Go, Areti Manola, Jyh-Ming Shoung and Stan Altan
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Inference for regression - Simple linear regression
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
1/2555 สมศักดิ์ ศิวดำรงพงศ์
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Copyright © Cengage Learning. All rights reserved. 13 Linear Correlation and Regression Analysis.
ACPS Advisory Committee Meeting October , 2002 ACPS Advisory Committee Meeting October , 2002 Scientific Considerations of Polymorphism in.
© 2004 Prentice-Hall, Inc.Chap 15-1 Basic Business Statistics (9 th Edition) Chapter 15 Multiple Regression Model Building.
Diploma in Statistics Introduction to Regression Lecture 2.21 Introduction to Regression Lecture Review of Lecture 2.1 –Homework –Multiple regression.
Basic Business Statistics, 11e © 2009 Prentice-Hall, Inc. Chap 8-1 Chapter 8 Confidence Interval Estimation Basic Business Statistics 11 th Edition.
Confidence Interval Estimation
Analysis and Visualization Approaches to Assess UDU Capability Presented at MBSW May 2015 Jeff Hofer, Adam Rauk 1.
Analytical considerations in the dissolution testing of oral modified release products Graham Clarke Bristol-Myers Squibb Moreton, UK The British Pharmaceutical.
Topic 7 - Hypothesis tests based on a single sample Sampling distribution of the sample mean - pages Basics of hypothesis testing -
VI. Evaluate Model Fit Basic questions that modelers must address are: How well does the model fit the data? Do changes to a model, such as reparameterization,
Important informations
Audit Sampling: An Overview and Application to Tests of Controls
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Copyright © 2008 Pearson Education, Inc. Publishing as Pearson Addison-Wesley Chapter 8 Linear Regression.
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Predicting Physical Stability in Q1A(R) Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration.
What Impact should ICH Q8 have on ICH Q6A Decision Trees?
The USP Performance Test Dissolution Systems Suitability Studies Walter W. Hauck, Ph.D. USP Consultant Presentation to Advisory Committee for Pharmaceutical.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
1 Is it potent? Can these results tell me? Statistics for assays Ann Yellowlees PhD Quantics Consulting Limited.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
Applied Quantitative Analysis and Practices LECTURE#25 By Dr. Osman Sadiq Paracha.
Chapter 8: Simple Linear Regression Yang Zhenlin.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
Copyright © 2007 Pearson Education, Inc. Publishing as Pearson Addison-Wesley Slide 8- 1.
Logistic Regression. Linear regression – numerical response Logistic regression – binary categorical response eg. has the disease, or unaffected by the.
Product & Process Working Group February 26, 2002.
BUS 308 Entire Course (Ash Course) For more course tutorials visit BUS 308 Week 1 Assignment Problems 1.2, 1.17, 3.3 & 3.22 BUS 308.
In vitro - In vivo Correlation
DSCI 346 Yamasaki Lecture 1 Hypothesis Tests for Single Population DSCI 346 Lecture 1 (22 pages)1.
N. V. Hartvig - Setting Release Limits
STABILITY ?.
PV-Trend: A JSL Application for Trending Topics for Pharmacovigilance
Uncontrolled variation is the enemy of quality
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Statistical Computation Tools in Pharmaceutical Drug Development and Manufacturing Life Cycle Fasheng Li Ke Wang Pharmaceutical Statistics Worldwide.
Chapter 8 Part 2 Linear Regression
Diagnostics and Transformation for SLR
3. Use an in-line sensor to sense when the effects of tool wear...
Jyh-Ming Shoung and Stan Altan
Diagnostics and Transformation for SLR
Quality guidelines on impurities
GL 51 – Statistical evaluation of stability data
GL8 (R) – Stability testing for medicated premixes
Presentation transcript:

Statistical Evaluation of Dissolution for Specification Setting and Stability Studies Fasheng Li Associate Director, Pharmaceutical Statistics Worldwide R&D Pfizer, Inc 37th Annual MBSW Muncie, IN May 20, 2014

Motivation Dissolution routinely tested to provide in vitro drug release information Drug development: prediction of in vivo drug release profiles Quality control: assessment of batch-to-batch consistency Decision making during dissolution method and drug development Data based specification setting for USP <711> dissolution test Dissolution monitoring on stability Statistical assessment integral to decision making process. 2

Outline Setting Extended Release Dissolution Specifications Number of time points needed Case 1: Two-point spec Case 2: Three-point spec Evaluation of possible specifications Dissolution on Stability No significant linear trend observed Non-linear trend observed 3

Dissolution Specification Setting How many time points are necessary for setting dissolution specifications? Based on “Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations”, at least three points (early, middle, late) on the dissolution profile should be used to have specifications Are fewer than three time points sufficient? Are three time points enough? 4

Dissolution Spec Setting – Case 1 Mean disso profiles of three typical batches of a sustained release drug product Proposed to have specs at two time points (30 and 180 minutes) Team discussed to add a spec at either 15 or 60 minutes Specs at 30 and 180 minutes Add either 15 or 60 minutes? 5

Dissolution Spec Setting – Case 1 , An empirical first-order two-parameter non-linear regression model fit to the release profiles Goodness-of-fit of the model evaluated by a coefficient of determination R2-type measure Model appropriateness evaluated by the lack-of-fit test R2 = Release = A(1-e-bt) is a two-parameter Weibull model 6

Dissolution Spec Setting – Case 1 , Dissolution profiles defined well by a two-parameter release model Mathematically, any two points on the profile would be able to sufficiently define the release profile No need to add a third time point for specification Team agreed to set disso specifications without a third point Two-point spec 7

Dissolution Spec Setting – Case 2 Mean disso profiles of three typical batches of a extended release drug product Originally specs at 5 time points proposed; should 1 more be added to improve control? Question: How many time points are needed for setting dissolution specifications? 8

Dissolution Spec Setting – Case 2 , An empirical three-parameter non-linear regression model (Weibull ) fit to the release profiles Goodness-of-fit of the model evaluated by a coefficient of determination R2-type measure Model appropriateness evaluated by the lack-of-fit test Three-point spec R2 = The three-parameter Weibull model is sufficient and adequate to define dissolution profiles in this case Recommend three-time points for dissolution specifications 9

0.983 = 94% with three time points Brief Summary , Three-point specifications are apparently more advantageous than six-point specifications: Cost Savings Save 50% reducing from 6 to 3 time points Quicker Analytical Results Conformity Risk Reduction: Assuming the probability of passing USP <711> dissolution test at each time point is the same (e.g. 98%), the overall probability to pass: 0.983 = 94% with three time points vs. 0.986 = 89% with six time points 10

Evaluation of Dissolution Specifications , After Determining Number of Time Points Evaluate proposed dissolution specifications against USP <711> at each time point Recommend new dissolution specifications if necessary Statistical Approach Simulations performed on individual dissolution data at each of the specification time points to check the probabilities of passing different stages (L1, L2, and L3) of USP <711> dissolution test 11

USP <711> Dissolution Test Acceptance Criteria for Extended Release Drug Products 12

Evaluation of Dissolution Specifications Controlled release product specs: @1 hour: <= 30% @4 hours: 40-60% @24 hours: >= 80% Re-evaluate specs due to method change Data: 46 unique dissolution conditions Each have 6 to 96 individual disso profiles A total of 1578 disso profiles collected Current three-point specifications 50000 simulations performed on 46 dissolution data sets to check probabilities of passing USP <711> stages (L1, L2, and L3) 13

Acceptance Probability Evaluation of Dissolution Specifications Specifications Stage % of Disso Tests Acceptance Probability by Stage Lx Need Stage Lx Pass 100% by Stage Lx Mean StDev Q1: <= 25% Q4: 35-55% Q24: >= 80% L1 100.0 13.0 95.3 9.0 L2 87.0 52.2 98.5 2.9 L3 47.8 80.4 99.5 1.4 Q1: <= 30% Q4: 35-55% Q24: >= 80% 15.2 96.2 7.6 84.8 58.7 99.0 2.1 41.3 99.8 0.7 Q1: <= 30% Q4: 40-60% Q24: >= 85% 4.3 59.4 38.2 95.7 17.4 87.1 19.1 82.6 91.0 19.9 Comparable Specs Proposed Specs 14

Evaluation of Dissolution Specifications Controlled release product - recommended specifications for new dissolution method @1 hour: <= 30% @4 hours: 35-55% @24 hours: >= 80% Individual Dissolution Profiles Revised three-point specifications Mean Dissolution Profiles Revised three-point specifications 15

Brief Summary – Disso Spec Setting , The number of time points on dissolution profiles used for specification setting Can be justified by fitting a non-linear release model Based on the number of parameters of the non-linear release model Specifications at each time points Can be evaluated by performing simulations on dissolution data against USP <711> criteria Calculate the probability to pass USP criteria 16

Dissolution on Stability Dissolution usually monitored on stability as a numerical quality attributes with numeric specifications e.g. %Release at 6 hours should be between 40-60% Dissolution data may not have a significant linear trend along stability time Linear trends not significant Non-linear trends observed How to evaluate dissolution data on stability? Typical Q1E shelf life analysis not appropriate. 17

Dissolution on Stability – No Linear Trend Clear linear trend for the chemical impurity data ICH Q1E Analysis Appropriate Linear Trend ICH Q1E Analysis is not meaningful No overall statistically significant trend in dissolution at 10 hours No Statistically significant Linear Trend 18

Dissolution on Stability – No Linear Trend Shelf-life predicted based on the major chemical impurities: Apply linear regression analyses following the ICH Q1E guidance The risk of failing dissolution on stability will be quantified Make sure the risk of failing dissolution spec is low Utilize dissolution profiles tested at each of the stability time points 19

Dissolution on Stability – No Linear Trend A three-parameter Weibull model: %Release = A(1-exp(-b*tm)) fit to all mean or individual dissolution profiles at each of the stability time points for all registration stability batches The risk of failing dissolution at a future stability test time since time is not relevant can be quantified by Constructing prediction limits with confidence level p% Checking the limits against the spec of (45, 65) If the prediction limits are within the spec limits, the risk of failing a future average dissolution would be no more than 100-p% 20

Risk of Dissolution on Stability Model fit mean dissolution profiles of stability times points very well (R2 > 0.99) The risk of failing dissolution test on stability at a future time is no more than 0.9% Storage Condition Strength Nonlinear Model Parameters and Fit Statistics 99 % Pred Limits for Dissolution at 10hr 99 % Pred Limits Meet Spec (45, 65)? %Chance for a Future Disso Test to Fail A b m R2 P-value 25°C/60%RH 1 94.5 0.0176 1.711 0.9939 0.0000 49.6, 63.0 Yes 0.045 2 94.0 0.0147 1.760 0.9952 47.8, 59.7 0.012 3 94.8 0.0159 1.739 0.9960 49.5, 60.6 0.003 4 95.7 0.0142 1.777 0.9964 49.5, 60.1 5 96.2 0.0140 1.783 49.5, 60.8 6 94.4 0.0135 1.800 0.9955 48.3, 60.1 7 93.6 0.0107 1.867 0.9945 44.5, 57.4 Not the lower limit 0.865 30°C/75%RH 95.8 0.0180 1.714 0.9932 50.9, 65.3 Not the upper limit 0.669 0.0150 1.764 48.8, 60.9 0.0165 1.734 0.9940 49.7, 63.4 0.074 97.5 0.0149 1.756 0.9951 49.6, 62.1 96.6 0.0137 1.796 0.9950 49.2, 62.0 0.007 96.1 0.0132 1.811 48.9, 61.3 95.1 0.0108 46.2, 57.9 0.112 21

Dissolution on Stability – No Linear Trend Risk of failing disso on stability is < 0.9% 22

Dissolution on Stability – No Linear Trend Risk of failing disso on stability is < 0.7% 23

Dissolution on Stability – Non-linear Trend Extended release product: with a clear non-linear trend for dissolution data at x hours 24

Dissolution on Stability – Non-linear Trend Empirical model of: %Release at x hours = A(1-e-b*(t+t0)) can be fit to dissolution at x hours from manufacturing age for all registration stability batches Shelf life (in terms of manufacture age) can be predicted when the 95% confidence interval intersects with the spec limits Shelf life (in terms of stability storage age) can be determined by subtracting the manufacturing age of the initial stability time point (stability time 0 month) 25

Dissolution on Stability – Non-linear Trend Stability program started at 7.4 months of manufacturing age Predicted shelf life is about 54.5 -7.4 = 47.1 months 26

Brief Summary – Dissolution on Stability , Stability dissolution data often show no significant linear trends No significant linear or non-linear trend Dissolution profile data can be utilized to remediate the risk of meeting dissolution specifications More information used versus evaluate at 1 time point on the profile Non-linear trend Empirical non-linear model fit to stability data could help justify the prediction of shelf life 27

Summary Dissolution for extended release drug products facing decision makings in areas such as Setting Specifications Number of time points on the profile for spec Specification limits at the time points Dissolution on Stability No significant linear trend Non-linear trend Statistics will be able to contribute greatly in the above areas to make regulatory appealing decisions Statisticians need to work proactively with team scientists

Acknowledgment Kim Vukovinsky, Senior Director, Pharmaceutical Statistics, Worldwide R&D, Pfizer Inc.